Biotechnology Transfer

The transfer of technologies is one of the most relevant activities of ICGEB. Since 2001, over 70 agreements and collaborations for training, transfer of technologies and patent licensing have been concluded with industrial partners located in Argentina, Brazil, China, Cuba, Egypt, India, Iran, Pakistan, South Africa, Sri Lanka, Syria, Turkey, United Arab Emirates, United States of America, Uruguay and Venezuela. Most of the companies involved in these tech transfers are now producing biosimilars using ICGEB technologies. These products are not only sold on local markets but also successfully compete in the international arena.

The procedure to transfer ICGEB technologies foresees the finalisation of a Technology Transfer Agreement, which usually provides for a period of training in the ICGEB laboratories by a number of industrial partners' employees, a supply of genetically modified strains and the protocols for the production, purification and quality control of a specific biotechnological product. To provide further assistance, in some cases it is agreed that ICGEB scientists will assist the industrial partner while reproducing the process on its own premises.

A dedicated group of scientists and technicians operate at both the Trieste and New Delhi Components for technology transfer activities. A Biotech Transfer Unit for the development of technologies for biogeneric pharmaceuticals, industrial enzymes and other biomolecules with potential industrial applications, has also been established at the Cape Town Component.
 

Available Technologies

Recombinant Human Erythropoietin

Recombinant Human Interferon α2a

Recombinant Granulocyte Colony Stimulating Factor

Recombinant Human Insulin

Recombinant Human β Interferon 1B

Recombinant Human Interferon α2a and Pegylation of IFN α2a

Recombinant Granulocyte Colony Stimulating Factor and Pegylation of rhG-CSF

Recombinant Hepatitis B Surface Antigen (R-HBsAg) 

Strains4Plants (Bioinoculants and Biofertilizers)

Technology transfer beneficiaries are the sole responsible entity for the research, development and for the commercial use of the transferred technologies. Agreements with ICGEB do not include consultation and/or provision of certificates of analyses for biopharmaceutical regulatory purposes.

Link to ICGEB Patents

For further information on Biotechnology Transfer please contact:
Marco Baralle
Group Leader
Tel: +39-040-3757316
E-mail: marco.baralleicgeb.org  

 

Cod. Fisc. 90031700322

AREA Science Park
Padriciano 99
34149 Trieste, ITALY
Tel: +39-040-37571
Fax: +39-040-226555
icgebicgeb.org
Address book

 

 

 tl_files/iTunes_Badge_Color_master_10251024.png

 

tl_files/FB.png tl_files/Twitter_logo_blue-1def.png tl_files/rss.png
tl_files/LinkedIn-InBug-2CRev2.png tl_files/YouTube.png 

 

tl_files/News 2017/INTERREG/INTERREG_IT-SLO_FUND_RGB.jpg